While biomarkers, namely, B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are physiological measures predictive of HF progression, determined on the basis of their percentage change in concentration [14], and are deemed as surrogate endpoints in monitoring HF treatment response [15]. The gene discussed is NPPB; the disease is hydrops fetalis.